Investors

Tuesday, 27 May 2025, 13:00 BST


Roche has published its First Quarter Sales for 2025 prior to the opening of the Swiss Stock Exchange on Thursday, 24th April 2025.




patients were treated with Roche medicines in 2024

Roche Diagnostics test were delivered to customers worldwide in 2024

Core investments in research and development in 2024: CHF 13.2 billion

Product PipelineWhy Invest

Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.

Dr Thomas Schinecker

CEO Roche Group

Investor updates

View all updatesView ad-hoc announcementsSubscribe

Upcoming Investor events

View all events

Roche Diagnostics Investor Day 2025Investors

May 27, 2025 at BST | London, UK

Bernstein 39th Annual Strategic Decisions Conference (SDC)Investors

May 28, 2025 at EDT | New York, US

BNP Paribas Exane 27th CEO ConferenceInvestors

June 03, 2025 at CEST | Paris, FR

Jefferies Global Life Science ConferenceInvestors

June 04, 2025 at EDT | New York, US

Barclays Conversations with the C-Suite 2025Investors

June 10, 2025 at CEST | Basel, Switzerland

Goldman Sachs 46th Annual Global Healthcare ConferenceInvestors

June 11, 2025 at EDT | Miami, US

Latest reports

Investor relations team contacts

Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.

View investor contact detail

Discover More